Document is current
Any future updates will be listed below
-
Authors
Pedrosa, Maurício Reis https://orcid.org/0000-0001-7966-2602
Franco, Denise Reis https://orcid.org/0000-0003-4961-0638
Gieremek, Hannah Waisberg https://orcid.org/0000-0002-5167-8212
Vidal, Camila Maia https://orcid.org/0000-0003-4251-4184
Bronzeri, Fernanda https://orcid.org/0000-0002-3660-3247
de Cassia Rocha, Alexia https://orcid.org/0000-0002-9616-8427
de Carvalho Cara, Luis Gabriel https://orcid.org/0000-0001-6678-0415
Fogo, Sofia Lenzi https://orcid.org/0000-0002-6390-5056
Eliaschewitz, Freddy Goldberg https://orcid.org/0000-0002-9283-1842
- License Information
-
More Information
Article History
Accepted: 1 August 2022
First Online: 31 August 2022
Declarations
:
: FG Eliaschewitz and D R Franco reports consulting fees from Eli Lily, NovoNordisk, AstraZeneca, and Sanofi-Aventis; payment or honoraria from Eli Lily, NovoNordisk, and Bayer; support for attending meetings and/or travel from NovoNordisk; and participation on a Data Safety Monitoring Board or Advisory Board for NovoNordisk and Pfizer.The other authors declare no conflicts of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
